Insider · CIK 0002048466
Adam Lezack
Files at BBNX (Beta Bionics, Inc.). First filing Nov 5, 2025, latest May 26, 2026.
In brief
Adam Lezack files SEC Form 4 as director at BBNX (Beta Bionics, Inc.). Since Nov 5, 2025, Adam Lezack has reported 0 open-market buys worth $0 and 3 open-market sells worth $100k, the latest filed on May 26, 2026.
A track record needs three past buys with six months of prices behind them; Adam Lezack has 0, so none is measured yet.
The newest scored trade: sold $21k of BBNX on May 21, 2026, filed May 26, 2026, scored 15 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 3 sells worth $100k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
BBNX: Beta Bionics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 15Weak | Beta Bionics, Inc. | $21k 1,998 shares | -16% | +20% from low-67% from high | |
| 21Weak | Beta Bionics, Inc. | $42k 1,406 shares | -14% | +204% from low-6% from high | |
| 14Weak | Beta Bionics, Inc. | $38k 1,406 shares | -13% | +180% from low0% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| May 21, 2026 | BBNX BETA BIONICS, INC. | 1,998 0.00% of outstanding | $20k | May 21, 2026 | none |
| Oct 31, 2025 | BBNX BETA BIONICS INC | 2,812 0.01% of outstanding | $75k | Oct 31, 2025 | none |
Transactions
Every row this insider has filed, 10 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 21, 2026 | BBNX Beta Bionics, Inc. | SOpen-market sale Common Stock10b5-1 | -1,000 | $9.95 | $9,950 | 11,432 | May 26, 2026 |
| May 21, 2026 | BBNX Beta Bionics, Inc. | AGrant or award Common Stock10b5-1 | +16,965 | $0.00 | $0 | 28,397 | May 26, 2026 |
| May 22, 2026 | BBNX Beta Bionics, Inc. | SOpen-market sale Comon Stock10b5-1 | -998 | $11.21 | $11k | 27,399 | May 26, 2026 |
| Jan 13, 2026 | BBNX Beta Bionics, Inc. | AGrant or award Common Stock | +3,997 | $0.00 | $0 | 12,432 | Jan 14, 2026 |
| Dec 1, 2025 | BBNX Beta Bionics, Inc. | SOpen-market sale Common Stock10b5-1 | -906 | $29.35 | $27k | 8,935 | Dec 2, 2025 |
| Dec 1, 2025 | BBNX Beta Bionics, Inc. | SOpen-market sale Common Stock10b5-1 | -500 | $29.91 | $15k | 8,435 | Dec 2, 2025 |
| Oct 31, 2025 | BBNX Beta Bionics, Inc. | SOpen-market sale Common Stock10b5-1 | -1,368 | $26.85 | $37k | 9,879 | Nov 5, 2025 |
| Oct 31, 2025 | BBNX Beta Bionics, Inc. | SOpen-market sale Common Stock10b5-1 | -38 | $27.70 | $1,053 | 9,841 | Nov 5, 2025 |
| Mar 15, 2025 | BBNX Beta Bionics, Inc. | AGrant or award Common Stock | +11,247 | $0.00 | $0 | 11,247 | Mar 18, 2025 |
| Jan 31, 2025 | BBNX Beta Bionics, Inc. | AGrant or award Director Stock Option (right to buy)derivative | +9,137 | $0.00 | $0 | 9,137 | Feb 3, 2025 |
Questions about Adam Lezack
Answered from the filings on this page, as of the latest one.
Is Adam Lezack buying or selling?
In the last 12 months Adam Lezack reported 0 open-market buys worth $0 and 3 open-market sells worth $100k on SEC Form 4; the latest was sold $21k of BBNX on May 21, 2026. Grants, option exercises and tax withholding are not counted.
How did Adam Lezack's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Adam Lezack has 0.
Where does Adam Lezack file Form 4?
Adam Lezack has filed Form 4 at BBNX (Beta Bionics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.